Innovative Chemistry Platform Generating Therapeutics for Neurodegenerative Diseases
First-in-class small molecules modulating three known processes involved in neurodegeneration: protein misfolding, oxidative stress and neuro-inflammation
Our Trojan Horse
Ilios is the ancient name of Troy. Our Trojan Horse delivers multi-functional drugs to the brain to combat neurodegeneration.
Multi-functional
Small Molecules
Modulating three known disease processes: protein misfolding, oxidative stress and neuro-inflammation
Novel Chemistry, Validated Agents
Merging privileged bioactive pharmacophores with glutathione and fatty acids to create proprietary brain-penetrant small molecules
Intelligent Drug Discovery
Ilios’ proprietary library of compounds is a cutting-edge machine learning training set to generate novel therapeutics
Modular
Platform
Facilitating rational design of treatments for multi-factorial diseases, including ALS, Frontotemporal Dementia, Parkinson's, and Alzheimer's Disease
Novel approach to neurodegeneration
Modulate multiple complementary mechanisms with a single drug
First in class small molecules optimized to module three known processes that play a key role in neurodegeneration: protein misfolding, oxidative stress, and neuro-inflammation
Synergistic activity in rationally designed NCEs merging validated naturally occurring ligands
Our modular chemistry platform merges bioactive pharmacophores with Glutathione and Fatty Acids to create New Chemical Entities (NCEs). These are designed to synergistically modulate multiple mechanisms involved in neurodegeneration
Delivering superior molecules using an innovative med-chem approach
-
Chemistry platform and lead program de-risked by decades of research
-
Components have demonstrated activity against protein misfolding, oxidative stress and neuro-inflammation
-
Merging ligands overcomes efficacy and drug-like property limitations of individual components
-
No novel biology: three processes targeted are known drivers of disease pathophysiology
-
-
On track to deliver lead candidate by H1 2025
Our first indication is ALS
